Moderna Inc (MRNA) Options

Kennedy has downplayed concerns about his anti-vaccine sentiments, saying in a Senate hearing that “all of my kids are vaccinated, and I believe vaccines have a critical role in healthcare.”

FDA Issues Back-to-Back Vaccine Approvals as RFK Jr. Takes HHS Seat

As they say, history repeats itself
https://www.biospace.com/fda/fda-issues-back-to-back-vaccine-approvals-as-rfk-jr-takes-hhs-seat

Cancer Vaccines: https://finance.yahoo.com/news/cancer-vaccines-market-track-major-180000959.html

Leading cancer vaccine companies such as IO Biotech, Merck, Moderna, Candle Therapeutics, ISA Pharmaceuticals, PDS Biotechnology, PDC*line Pharma, LG Chem, AVEO Oncology, Archival Farma, and others are developing novel cancer vaccines that can be available in the cancer vaccines market in the coming years.

Some of the key cancer vaccines in the pipeline include IO102-IO103, mRNA-4157 (V940) + KEYTRUDA, CAN-2409, Nelipepimut-S + Cemiplimab, PDS0101 + Pembrolizumab, PDC*lung01, LB-LR1109, RUTI, and others.

Scientists Crack The Code For Delivering MRNA Medicine To The Brain

https://scienceblog.com/scientists-crack-the-code-for-delivering-mrna-medicine-to-the-brai/

Unpacking the lies

~~~ That we've been fed ~~~
(3:04)

Get the truth instead

NaturalNews

To learn more, visit: https://discover.brighteon.com/unpacking-the-lies-weve-been-fed

RFK Jr.

Moderna Earnings: Maintaining Our $102 Fair Value Estimate as Long-Term Pipeline and Strategy Intact

https://www.morningstar.com/company-reports/1264965-moderna-earnings-maintaining-our-102-fair-value-estimate-as-long-term-pipeline-and-strategy-intact?listing=0P0001F631

Antidepressant, it's no use......it's just harmful...
$MRNA

Not much repeat business

In that model

What is an Antidepressant

Why is it called for

Personalities

Can be damaging

To the hive mind

How is it currently made

Take out all poisons

Starting point

RFK Jr. Outlines His Health Secretary Priorities in Post-Confirmation Interview With Fox News

‘I’m not going to take away anybody’s vaccine’

https://time.com/7222533/rfk-jr-health-human-services-secretary-confirmation-interview-fox-vaccines/

Revenue: $966 million vs. $942.8 million expected

RFK Jr. Is Already Taking Aim at Antidepressants

Conspicuously absent was any explicit mention of childhood vaccines, which Kennedy has long railed against as the head of the anti-vaccine advocacy group Children’s Health Defense.

https://www.motherjones.com/politics/2025/02/kennedy-rfk-antidepressants-ssri-school-shootings/

RFK Jr. Outlines His Health Secretary Priorities in Post-Confirmation Interview With Fox News

‘I’m not going to take away anybody’s vaccine’

https://time.com/7222533/rfk-jr-health-human-services-secretary-confirmation-interview-fox-vaccines/

Recent Progress and Upcoming Late-Stage Pipeline Milestones

The Company remains focused on a prioritized research and development portfolio, delivering up to 10 product approvals through 2027.

What does the confirmation of RFK Jr. mean

~~~ For FDA and Big pharma ~~~
(23:50)

Follow the data

This is historic
- RFK Jr. Confirmed as HHS Head: A Pivotal Moment (0:01)

- Censorship and Corruption in Government Agencies (1:34)

- Proposed Reforms and Legal Actions Against the FDA (2:24)

- Impact on the Nutrition Industry and Big Pharma (7:56)

- Concerns About Heavy Metals and GMOs (12:03)

- Calls for Criminal Prosecutions and Systemic Reform (17:16)

For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Cash Position: Cash, cash equivalents and investments as of December 31, 2024, were $9.5 billion, compared to $9.2 billion as of September 30, 2024. The increase during the quarter was primarily attributable to the timing of accounts receivable collections.

https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx

Senate confirms RFK Jr. as HHS secretary in 52-48 vote

https://www.foxnews.com/politics/senate-confirms-robert-f-kennedy-jr-serve-trumps-health-secretary

How about you read the paper first before we have a serious discussion?
https://www.iovance.com/uploads/Chesney-JITC-2022-Efficacy-and-safety-of-lifileucel-TIL-cell-therapy-in-pts-w-adv-melanoma-after-pr-2447-publication.pdf

While you read papers on cell therapy, keep one question in your mind: can the treatment trigger massive and sustainable t-cell (CD4 & 8) infiltration into tumor sites after the treatment stops?

BTW, you don't happen to think that Merck would construct vaccine manufacturing facilities based on the following results on mRNA trials, do you?

https://clinicaltrials.gov/study/NCT03313778
https://pubmed.ncbi.nlm.nih.gov/39115419/

https://jitc.bmj.com/content/8/Suppl_3/A477.1
https://clinicaltrials.gov/study/NCT03313778

https://clinicaltrials.gov/study/NCT05933577
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS9616

https://s29.q4cdn.com/435878511/files/doc_presentations/2024/Jun/03/asco-2024-adjuvant-melanoma.pdf
https://clinicaltrials.gov/study/NCT03897881

https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA9503
https://www.clinicaltrials.gov/study/NCT03897881

https://pubmed.ncbi.nlm.nih.gov/33016924/
https://clinicaltrials.gov/study/NCT03480152

Three Years After Experimental Vaccine, These Patients Are Still Cancer-Free

https://gizmodo.com/three-years-after-experimental-vaccine-these-patients-are-still-cancer-free-2000559585

From memory, one of three pivotal trials ongoing. I know they were planing to start a few more PhI/II trials, including one in pancreatic (based on BNTX data*).

* https://www.nature.com/articles/s41586-023-06063-y https://www.globenewswire.com/news-release/2024/04/07/2858841/0/en/Three-year-Phase-1-Follow-Up-Data-for-mRNA-based-Individualized-Immunotherapy-Candidate-Show-Persistence-of-Immune-Response-and-Delayed-Tumor-Recurrence-in-Some-Patients-with-Resec.html

The vaccine targets five antigens VHL, PBRM1, BAP1, KDM5C, PIK3CA.

From the paper: ''All patients generated T?cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA.'' https://www.nature.com/articles/s41586-024-08507-5

MRNA's vaccine targets up to 34 patient-specific neoantigens.

DCVax-L in combination with poly-iclc can certainly fix those highly mutated genes.

There is a reason why NWBO has never disclosed or talked about this trial. NWBO's -L isn't a gene therapy either.

Can you imagine the magnitude of efficacy that the latest version of DCVax-L in combination with keytruda can bring after dendritic cells present hundreds of tumor-associated antigens to immune system?

Again, there is a reason why NWBO has never disclosed or talked about this trial. Also, if a mutation is never transcribed, translated and processed, it cannot stimulate an immune response from T-cells. Looking at the data from Dr Rosenberg's group at the US NCI, as well as others, only approximately 1-6% of the mutations are actually transcribed, translated and processed, presented on the surface and can be recognised by the patient's own T-cells using current methods https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30374-3 https://aacrjournals.org/cancerdiscovery/article/9/8/1022/41919/Unique-Neoantigens-Arise-from-Somatic-Mutations-in https://ascopubs.org/doi/10.1200/JCO.21.02170

The vaccine targets five antigens VHL, PBRM1, BAP1, KDM5C, PIK3CA. It happens that some of those antigens also exist in three types of brain tumors. DCVax-L in combination with poly-iclc can certainly fix those highly mutated genes. Here I am talking about the version of DCVax-L developed fifteen years ago. Can you imagine the magnitude of efficacy that the latest version of DCVax-L in combination with keytruda can bring after dendritic cells present hundreds of tumor-associated antigens to immune system?

https://www.nature.com/articles/s41586-024-08507-5

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of a first-in-human, phase 1 clinical trial of CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) CAR-M in patients with advanced HER2-overexpressing tumors. Fourteen patients were treated across two different regimens. Patients with breast cancer and gastroesophageal cancer were primarily enrolled and had to have demonstrated overexpression of HER2 according to the American Society of Clinical Oncology/College of American Pathologists guidelines (HER2 immunohistochemistry 3+ or immunohistochemistry 2+/in situ hybridization-amplified). No lymphodepletion chemotherapy was used before infusion. The primary endpoints were safety and CAR-M manufacturability. Secondary endpoints included cellular kinetics and efficacy using objective response rate, overall survival, progression-free survival and duration of response. No dose-limiting toxicities, severe cytokine release syndrome (≥grade 3) or immune effector cell-associated neurotoxicity syndrome were observed; 44% (n?=?4 of 9, 95% confidence interval?=?14–79%) of HER2 3+ tumors achieved stable disease as best overall response 8 weeks after treatment. No meaningful activity was observed in the HER2 2+ population (n?=?5). Correlative analyses of serial biopsies confirmed that CT-0508 traffics to and remodels the tumor microenvironment, resulting in expansion of CD8+ T cells. These findings demonstrate the preliminary safety, tolerability and manufacturing feasibility of CT-0508 for HER2+ tumors. ClinicalTrials.gov registration: NCT04660929.

https://www.nature.com/articles/s41591-025-03495-z

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

https://ir.carismatx.com/news-releases/news-release-details/carisma-and-moderna-expand-collaboration-develop-two-vivo-car-m

data before the market opens on Friday, February 14th. Analysts expect Moderna to post earnings of ($2.86) per share and revenue of $951.09 million for the quarter

"there's more" A Phase 3 Non-small Cell Lung Cancer

https://www.merck.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-after-neoadjuvant-keytruda-and-chemotherapy-in-patients-with-certain-ty/

https://clinicaltrials.gov/study/NCT06077760?term=mRNA-4157&rank=5

A randomised and double-blind PhII is ongoing https://clinicaltrials.gov/study/NCT06307431

https://x.com/moderna_tx/status/1887234640806658174

$MRNA

Nine patients with advanced kidney cancer who received an experimental vaccine tailored to their tumors’ specific mutations mounted an immune response to their disease and remained cancer-free for three years, an early-phase clinical trial has shown.

https://gizmodo.com/three-years-after-experimental-vaccine-these-patients-are-still-cancer-free-2000559585

https://www.nature.com/articles/s41586-024-08507-5

Understanding what cancer is

Will lead to its prevention

Breaking the matrix

Moderna needs to buyout RNAZ cure to cancer vaccine and burn the dirty rat shorts that suppressed the only hope for terminally ill cancer patients

kennedy getting approved will put this dn even more---sure paid off for that bozo to pull out of the race and kiss the donalds arrrrrrrrrrrrrs

Work finishes on Moderna Innovation and Technology Centre in Oxfordshire

Construction is now complete on the Moderna Innovation and Technology Centre (MITC), the pharma firm’s new research, development and manufacturing facility at Harwell Campus in Oxfordshire.

Subject to licensure, the first product manufactured at scale at the centre is expected to be a Covid-19 vaccine to support the NHS vaccination programme.

In the event of a pandemic, the site will have the capacity to produce a minimum of 250 million vaccine doses per year.

The MITC also features labs and office spaces to support high-priority pre-clinical and clinical-stage assays.

Its biomarker, bioanalytical, and molecular assay laboratories will process samples from Moderna’s clinical trials to assess the safety and effectiveness of potential therapeutics and vaccines.

Stephen Hoge, MD president of Moderna, said: “We’re immensely proud of our new manufacturing facility and clinical laboratories in Oxfordshire and the significant and ongoing investment into R&D across the UK.

“By investing heavily across clinical trials and research, we aim to drive breakthroughs that could improve patient outcomes, support the UK healthcare ecosystem and ultimately shape the future of medicine.”

Moderna has launched 23 clinical trials in the UK across 110 sites since 2021, involving more than 12,700 people.

It has an ongoing 10-year strategic partnership with the UK government, managed by the UK Health Security Agency (UKHSA).

Prof Dame Jenny Harries, chief executive of the UKHSA, added: “The Covid-19 pandemic demonstrated how government can and must work closely with industry to respond to emerging health threats.

“Our partnership with Moderna exemplifies these opportunities and will support the UK’s ambitions towards the 100 Days Mission, help put the UK at the forefront of new technologies and drive economic growth.

"The completion of construction of this impressive facility marks a real milestone and doing so in less than two years is a remarkable achievement.

“Once regulated, it will help ensure the NHS has rapid access to mRNA vaccines if needed in a future pandemic, as well as open doors to new vaccine products.”

The event at Harwell coincided with the first meeting of the new government’s joint oversight committee, co-chaired by Georgia Gould MP, parliamentary secretary at the cabinet office, and Moderna President, Stephen Hoge.

The committee discussed the progress of their partnership and toured the facility, which is expected to be fully operational later this year.


https://thebusinessmagazine.co.uk/technology-innovation/work-finishes-on-moderna-innovation-and-technology-centre-in-oxfordshire/

Farmers in bird flu 'panic' call for UK vaccine plan

https://www.bbc.com/news/articles/crm7d2yv878o

bad news

When Donald Trump unveiled a $500bn plan to spearhead a cancer vaccine, many greeted it as another of his grandiose proposals.

But not Anna Bochenski.

The 53-year-old New Yorker is one of the few people in the world who knows how life-changing the shots can be.

symbol



The administrative worker was told she had just months to live in January 2021 after her aggressive breast cancer returned and stopped responding to treatment.

After a six-year battle with the disease, which included numerous surgeries and 32 brutal rounds of radiation, the cancer had spread to her ribs and spine, where it had become virtually incurable, known as 'metastatic'.

As a last resort, she was enrolled in a clinical trial for an experimental cancer vaccine developed at the famous Mount Sinai hospital in Manhattan.

The vaccine works by melting away the primary tumor and teaches the body to hunt and kill the cells that have spread elsewhere. Within weeks, the tumors in her back and a tennis ball-sized tumor under her armpit disappeared, while a third in her chest shrunk.

Speaking to DailyMail.com this month, almost exactly four years after the vaccine, she said: 'It saved my life. At that time, there was nothing I could do. There was nothing that could treat my cancer.'

Hundreds of experimental cancer vaccines are in production around the world, but President Trump's newly announced artificial intelligence project could be the catalyst that finally brings these shots to the public.

https://www.dailymail.co.uk/health/article-14322495/cancer-vaccine-donald-trump-mrna-cure-tumors.html

Fetterman: RFK Jr.’s nomination in trouble after rocky hearing

Sen. John Fetterman (D-Pa.), who was thought to be open to voting for Robert F. Kennedy Jr.’s nomination to head the Department of Health and Human Services, now says the nominee is in serious trouble after his rocky confirmation hearing.

“I don’t think it went well for him today. I don’t think that was a good one,” he said after Kennedy sparred with Democrats on the Senate Finance Committee over his past statements and stance on vaccines.

Fetterman said after the bruising hearing that he thinks Kennedy’s nomination may be “moot.”

“It’s moot,” he said when asked if he’s still open to voting for Kennedy. “I’m not really sure how much support’s going to emerge after that.”

The Pennsylvania Democrat noted that he’s met with Kennedy twice already.

“I think we can all agree that was really a difficult performance,” he said. “I’m not sure he’ll even make it out of the committee.”

Sen. Michael Bennet (D-Colo.), one of the Democrats who grilled Kennedy at his hearing Wednesday, asked him pointedly about his comments on a podcast that exposure to pesticides could be causing more children to identify as transgender.

Kennedy acknowledged under Bennet’s cross-examination that he “probably did say” that Lyme Disease was a militarily-engineered bioweapon.

Sen. Ron Wyden (D-Ore.), meanwhile, tried to pin down Kennedy on his past views and statements on vaccines in a combative back-and-forth.

“You have a history of trying to take vaccines away from people,” Wyden told him.

RFJ, Jr.’s nomination will be voted on by the Senate Finance Committee, but before that happens, he will appear before the Senate Health, Education, Labor and Pensions Committee for a second round of questioning Thursday.

Sen. Susan Collins (R-Maine), a member of the HELP Committee and a key Senate swing vote, said it’s “premature” for her to say how she will vote.

“I do not make decisions on nominees prior to the public hearings,” she said.

“It’s totally premature to make a decision prior to the [public hearing,]” she added.

https://thehill.com/homenews/senate/5114271-fetterman-rfk-jr-nomination-hearing/

It Took RFK Jr. Just Six Minutes to Lie to Congress

https://www.motherjones.com/politics/2025/01/rfk-jr-confirmation-hearing-vaccines/

As the Senate committee hearings over Robert F. Kennedy Jr.’s nomination to serve as secretary of Health and Human Services kick off Wednesday, opposition to his bid is mounting.


"All we need is a handful of senators," says Dr. Rob Davidson, executive director of Committee to Protect Health Care, a progressive advocacy group that reports gathering more than 18,000 signatures from physicians (though the list hasn't been made public). "They should look at his record and it will absolutely confirm that he is a danger."

let's see what will happen

https://www.npr.org/sections/shots-health-news/2025/01/28/nx-s1-5274744/rfk-confirmation-vaccines-health-secretary

Are vaccines the solution to every problem?

Difficult to know whose side to take

Without the proper information on safety and efficacy.

UK confirms 'rare' human case of bird flu

https://medicalxpress.com/news/2025-01-uk-rare-human-case-bird.html

https://www.nature.com/articles/d41586-025-00245-6

this company controls a monster breakthrough technology,
the financial management of the company has allowed itself to be boxed in the corner by manipulative Wall Street crooks using large warrant issuance to control the shares. Today, we do not even know exactly how many zillions of warrants are outstanding!

The company filings and corporate presentation are grossly outdated

moderna it's another world.

Good luck my friend

The cure to cancer brother🚀🚀🚀
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary platform delivery system to defeat cancer, today announced a strategic expansion of its diverse product portfolio. New capabilities for TransCode’s TTX delivery platform are embodied in the new provisional patent application entitled, “Nanoparticles Comprising Payloads and Their In Vivo Delivery” (U.S. patent application 63/456,602 or the ‘602 application).

The therapeutic potential of RNA in oncology has remained an unrealized promise due to what is believed to be the difficulty in safely and effectively delivering oligonucleotides to tumors. Despite well documented targets that have been shown to be important for cancer onset, progression and recurrence, delivery mechanisms have fallen short in delivering RNA therapeutic payloads due to systemic inflammation, toxicity and the inability to efficiently reach their targets. Additionally, targeted delivery of therapeutic agents outside of RNA approaches has also remained a significant challenge for treatment of many other diseases besides cancer.

The technology disclosed in the ‘602 application represents an expansion of TransCode’s therapeutic delivery platform to include applicability to gene editing by repairing and/or replacement of genes using CRISPR technology and cancer vaccines using messenger RNA (mRNA).

TransCode’s said, “Our scientists have been working to expand the potential of our nanoparticle delivery system for some time in order to overcome the challenges of targeted delivery of therapies in oncology. We believe that by expanding our delivery platform and our resulting product portfolio including CRISPR, mRNA vaccines and potentially other targeted therapies outside of RNA positions the company as a platform delivery company.”

The filing of the ‘602 application directly supports TransCode’s goal of deploying the right therapy for individual cancer patients. If issued, the proposed patent would join other granted patents controlled by TransCode, including US 9,629,812 and EP 2 961 386. As part of its overall patent strategy, TransCode is actively pursuing intellectual property protection for additional components of its discovery engine built around its TTX delivery platform. The TTX platform currently comprises a hemodynamic and metabolic targeting delivery system suitable for deploying a variety of therapeutic candidates including RNAi, pattern recognition receptors, mRNA, gene repair/replacement and radiolabeled therapeutics.

“While our major focus is on advancing TTX-MC138, our lead therapeutic candidate targeting miR-10b, shown to be a master regulator of metastatic cell viability in a number of solid tumor types, we are excited by our platform’s expanded potential to be used more broadly for a variety of therapeutic approaches to relevant documented targets responsible for cancer onset, progression and recurrence. The approach represented by the ’602 application, if successful in development, could expand our ability to deploy the right therapy for individual patients using the therapeutic capabilities our platform offers.”

Donald Trump's most impactful move could be to spearhead the world's first cancer vaccine-

This way, patients with the earliest forms of the disease could be identified and treated before the cancer spreads.
We will be amazed at how quickly we're curing this cancer and that one and heart disease and what this will do for the ability to deliver very high quality healthcare... to cure the diseases at a rapid rapid rate.

Similar experimental mRNA cancer vaccines have been in development since the technology was advanced during the Covid pandemic.

https://www.dailymail.co.uk/health/article-14314159/Trumps-radical-500billion-plan-end-cancer-VACCINE.html

$MRNA let's see what will happen

What is an immune system

Why would it need help

How does it get compromised

Create a problem

Offer solution

What a perpetual

Business plan

Norovirus-A large phase three trial of the shot is underway, with results expected as soon as later this year or 2026. Moderna needs to see a certain number of cases before it can analyze the data and determine how well its vaccine works, putting the timeline in flux. The 25,000-person study is enrolling ahead of schedule, said Doran Fink, Moderna’s clinical therapeutic area head for gastrointestinal and bacterial pathogens.

https://www.modernatx.com/en-US/media-center/all-media/blogs/understanding-norovirus

Donald Trump Backing mRNA Vaccine Project Gets Backlash

https://www.newsweek.com/donald-trump-mrna-vaccine-cure-cancer-ai-2018701

$MRNA

Larry Ellison of Oracle: AI will design mRNA vaccines for every individual person against cancer — making them robotically in 48 hours.

"This is the promise of AI."



In a White House briefing on Tuesday, President Donald Trump unveiled the Stargate Project, a $500 billion private sector initiative led by OpenAI, SoftBank, and Oracle.

https://www.maginative.com/article/softbank-openai-and-oracle-launch-500-billion-ai-infrastructure-initiative/

Avian influenza outbreak in Georgia halts sale of poultry, forces quarantine

Poultry capital of the world


https://www.fox5atlanta.com/news/avian-influenza-outbreak-georgia-halts-sale-poultry-forces-quarantine

Moderna is preparing to advance mRNA-1018 into Phase 3. The Company looks forward to sharing the Phase 1/2 results at an upcoming scientific meeting.

Moderna Announces Updates on Pandemic Influenza Program

US awards Moderna $590 million for bird flu vaccine development

I didn't expect it honestly, wasn't mrna technology very bad?! 😅

https://investors.modernatx.com/news/news-details/2025/Moderna-Announces-Updates-on-Pandemic-Influenza-Program/default.aspx

Government starting new virus MRNA When you can’t beat them, you join them🤑🤑🤑🤑

https://www.benzinga.com/insights/analyst-ratings/25/01/43012803/moderna-stock-a-deep-dive-into-analyst-perspectives-10-ratings